Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders

CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that tumors expressing low CDK6 rely on CDK4 function, and are exquisitely sensitive to CDK4/6i. In contrast, tumor cells expressing both CDK4 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xuewei, Yang, Xiaobao, Xiong, Yan, Li, Ruitong, Ito, Takahiro, Ahmed, Tamer A., Karoulia, Zoi, Adamopoulos, Christos, Wang, Hong, Wang, Li, Xie, Ling, Liu, Jing, Ueberheide, Beatrix, Aaronson, Stuart A., Chen, Xian, Buchanan, Sean G., Sellers, William R., Jin, Jian, Poulikakos, Poulikos I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462800/
https://www.ncbi.nlm.nih.gov/pubmed/34568836
http://dx.doi.org/10.1038/s43018-021-00174-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462800/
https://www.ncbi.nlm.nih.gov/pubmed/34568836
http://dx.doi.org/10.1038/s43018-021-00174-z

Ejemplares similares